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Abstract Fungal infections in children rarely occur, but
continue to have a high morbidity and mortality despite the
development of newer antifungal agents. It is essential for
these infections to be diagnosed at the earliest possible
stage so appropriate treatment can be initiated promptly.
The addition of high-resolution computer tomography (HR
CT) has helped in early diagnosis making; however, it
lacks both sensitivity and specificity. Metabolic changes
precede anatomical changes and hybrid imaging with
positron emission tomography (PET) integrated with
imaging modalities with high anatomical resolution such as
CT or magnetic resonance imaging (MRI) is likely to
detect these infections at an earlier stage with higher
diagnostic accuracy rates. Several authors presented papers
highlighting the advantages of PET/CT in imaging fungal
infections. These papers, however, usually involve a lim-
ited number of patients and mostly adults. Fungal infec-
tions behave different in children than in adults, since there
are differences in epidemiology, imaging findings, and
response to treatment with antifungal drugs. This paper
reviews the literature and explores the use of hybrid
imaging for diagnosis and therapy decision making in
children with fungal infections.
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Introduction
Fungal infections may be superficial, mucous, or invasive.
Most superficial and some mucous fungal infections are
easily accessible and can be diagnosed by clinical findings
and microscopy. No diagnostic imaging modalities are
necessary in those cases. On the other hand, in a few
mucous and in most invasive fungal infections (IFIs),
which may not be easily accessible, a proper diagnosis is
essential and existing imaging techniques are of invaluable
importance. In the past few decades, there has been a
considerable increase in both the frequency and importance
of IFIs [1]. This increase is directly related to the growing
population of immunocompromised individuals, resulting
from changes and advances in medical practice such as the
use of intensive chemotherapy, immunosuppressive drugs,
and growing stem cell transplantation possibilities. HIV
and other diseases which cause immunosuppression have
also contributed to this problem.
Children at risk of acquiring IFIs are children who
undergo chemotherapy for malignancy, are treated with
immunosuppressive drugs, have congenital or acquired
immune deficiencies, and undergo hematopoietic stem cell
transplantation (HSCT) or solid organ transplantation
(SOT) [1, 2]. These diseases and/or treatment regimens
represent ‘‘typical’’ risk factors for acquiring an IFI. Fur-
thermore, neonates or children admitted to the intensive
care unit (ICU) may also be at risk of developing IFIs. The
children admitted to the ICU may or may not be neu-
tropenic [3].The epidemiology and risk factors for IFIs are
different for previously healthy children who have been
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admitted to the ICU compared to children with malignant
or hematologic disorders [4]. The risk factors of acquiring
an IFI for children admitted to the ICU include critical
illness with long stay in ICU, prolonged use of antibiotics,
abdominal surgery particularly with bowel anastomosis,
insertion of central venous catheters or other foreign bodies
into the blood vessels and low birth weight or prematurity
in neonates [4]. A child on admission at the ICU may also
have any of the typical risk factors for IFIs.
Candida and Aspergillus are the most common fungal
agents responsible for IFIs. In children, invasive candidi-
asis occurs five times more frequent than invasive
aspergillosis. On the contrary however, the mortality rate is
2.5–3.5 times higher for invasive aspergillosis compared to
invasive candidiasis [4, 5]. The overall mortality rate
attributable to patients with IFIs is 32 % [6]. The mortality
rate for invasive aspergillosis is 70 % despite appropriate
treatment, whereas it is between 20 and 30 % for invasive
candidiasis [5, 7]. It is important to prevent these infec-
tions, and when they occur, IFIs must be diagnosed as early
as possible and appropriate treatment should be initiated
immediately.
Pathogens
In general, fungi are classified into yeasts and molds with
Candida species (Candida sp.) and Aspergillus species
(Aspergillus sp.) being the most common type of each.
Candida
Invasive Candida infection is the fourth most occurring
blood stream infection in ICUs [8]. Candida albicans (C.
albicans) is the most common cause of invasive candidi-
asis; however, in recent years, with the introduction of
antifungal prophylaxis, there has been a reduction in the
proportion of invasive candidiasis due to C. albicans, but
an increase in cases of IFIs caused by less common Can-
dida sp. such as C. krusei, C. parapsilosis, and C. glabrata
amidst others which may vary in virulence and suscepti-
bility to the antifungal drugs commonly used [8].
C. glabratra has emerged as an important pathogen in
Northern Europe, the USA, and Canada, whereas C.
parapsilosis is more prominent in Southern Europe, Asia,
and South America. C. parapsilosis is less virulent than C.
albicans and C. glabrata, and hence, it has lower mortality
rates. Invasive candidiasis usually presents as candidemia
with fever and sepsis. It may also occur as a blood culture
negative syndrome such as disseminated (hepatosplenic)
candidiasis with deep-seated infections in other organs
such as bones, muscles, joints, and eyes, usually occurring
in patients with hematologic cancer or disorders. These
infections arise from an earlier or previously undiagnosed
blood stream infection [8, 9].
Aspergillus
Invasive aspergillosis is still a major cause of morbidity in
severely immunocompromised patients. There are many
species, and Aspergillus fumigates is the most common.
Invasive aspergillosis presents with cough, dyspnea, pleu-
ritic chest pain, and sometimes hemoptysis. It frequently
occurs among patients with the typical risk factors and it is
increasingly diagnosed in patients without the typical risk
factors for IFIs in patients who are treated on the ICU with
burns, trauma, or liver cirrhosis [4, 7, 10].
Other fungal pathogens
While Candida and Aspergillus remain the two main fungi
encountered in IFIs, less common organisms such as
Cryptococcus sp., Histoplasmosis sp., Coccidiomycosis sp.,
Cryptococcus sp.,Murcomycosis sp., and Blastomycosis sp.
may also be etiological agents. Each of these has its
specific characteristics. For example, Histoplasmosis sp.
usually involves the reticuloendothelial system and fre-
quently affects the adrenal glands, while Cryptococcus sp.
may occur more commonly in HIV patients. These rare
fungi have all been diagnosed in children [11, 12].
Differences in IFIs between children and adults
Although children and adults are similarly vulnerable to
IFIs, important differences exist in host responses, the
capacity of immune reconstitution after chemotherapy, and
comorbidity. These differences all influence the risk and
outcome of IFIs [13]. In the neonatal period, neutrophils
have impaired chemotaxis and bactericidal activity com-
pared with older children and adults [14, 15]. Furthermore,
T cell regeneration, both in number and repertoire, fol-
lowing intensive chemotherapy, critically depends on the
age of the patient [16]. The incidence of invasive can-
didiasis is higher in the pediatric age group, with the
highest risk in neonates [17, 18]. Candida infections in
older children are more similar to those in adults. In chil-
dren aged younger than 1 year, the incidence of C. para-
psilosis is considerably higher than that of C. glabrata,
whereas in adolescents, the incidence of C. glabrata may
exceed the incidence of C. parapsilosis [19]. Overall, the
rate of mortality due to invasive candidiasis is lower in
children compared with adults [20].
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Invasive aspergillosis, in contrast to invasive candidia-
sis, is rare in neonates, but occurs more frequently in older
children. The overall fatality rate of invasive aspergillosis
varies from 53 %, similar to that seen in adult patients, to
as high as 70 % [5, 21] and it significantly contributes to
the mortality of immunocompromised children. In a large
national retrospective study in the USA, 18 % of children
with invasive aspergillosis died in the hospital, compared
to 1 % of similarly immunocompromised children without
invasive aspergillosis [22].
Relatively little is known regarding Mucormycosis in
children. A systematic literature review including reports
back to 1939 identified a total of 157 reported children with
Mucormycosis [23]. Whereas prematurity was the most
common risk factor in pediatric patients, diabetes and
underlying malignancy were seen in both children and
adults developing invasive mucormycosis. Compared with
children, the mortality of Mucormycosis appeared to be
lower in adults, which might be due to a lower rate of
dissemination [24].
Diagnosis
The armamentarium available for diagnosing IFIs includes
direct or indirect methods of detection [25]. No test is
perfect and it is necessary to perform several diagnostic
tests to achieve maximum accuracy [25]. Direct methods
include the demonstration of fungal elements in blood or
body fluids by microscopy and culture or from tissue by
histopathology and culture of homogenized tissue. This can
only be achieved by getting samples with invasive proce-
dures from patients. In some cases, such as pulmonary
aspergillosis, this is difficult to perform because of the risks
associated with taking a lung biopsy in a sick child in
whom contraindications for invasive procedures like
thrombocytopenia may be present.
Culture allows the identification of types and species of
the fungi and provides a means of testing susceptibility of
the fungi to antifungal agents. However, culture is a time-
consuming process which is a major limitation as it delays
the onset of therapy. Moreover, the yield is suboptimal
(about 50–60 %) in cases where there is fungemia [26].
The results of histology may come faster but may only
identify fungi to a certain degree. This may help in starting
direct initial therapy but ultimately culture is needed to
properly define the fungi and conduct susceptibility tests
[26].
Indirect methods were introduced to try to overcome
some of the limitations of the direct methods, particularly
to reduce the time of diagnosis. Due to the high morbidity
and mortality, antifungal therapy is started empirically
when there is a high suspicion of fungal infection.
However, this leads to the exposure of patients who do not
have IFIs to antifungal therapy and thus the risk of adverse
reactions. Preemptive strategies where only patients con-
sidered very likely to have IFIs are identified and treated
have now been adopted by most ICUs. These strategies are
based on guidelines, which help identify these patients
[27]. Indirect methods play a major role in these guidelines
and include commercially available assays against antigens
in the fungal cell wall to detect galactomannan (GM) or b-
1,3-D-glucan (BDG) for detection of Aspergillus and most
fungal species, respectively [28].
Other indirect tests available include detection of DNA
sequences by polymerase chain reaction not only in blood
but also especially in bronchoalveolar washings and other
body fluids. GM is fairly specific for Aspergillus, but it
may have cross reactivity with GM present in the cell wall
of Penicillium sp. and other organisms. It has a very good
sensitivity, which has been found to perform well in both
children and adults in prospective studies. BDG is a com-
ponent of the cell wall of many pathogenic fungi and did
not perform as well in children as in adults [29]. These
assays have been introduced into the Revised European
Organization for Research Cancer Treatment Mycosis
Study Group (EORTC/MSG). The test in combination with
clinical (including radiological) findings allows one to
classify the diagnosis of IFI as definite, probably, or pos-
sible. This classification is for clinical trials and not nec-
essarily for diagnosis in the individual patient. The
classification emphasizes the difficulty in diagnosis of IFIs
[30].
The published data on specificity and sensitivity of
diagnostic approaches such as the Aspergillus galac-
tomannan (GM) test in the pediatric population are quite
limited [31]. This is because many clinical trials enroll
adult patients only, and because sub-analyses of pediatric
data from larger trials enrolling both pediatric and adult
patients, as well as prospective studies in children, are
limited in their interpretability by small patient numbers.
One study analyzed GM in 3294 serum samples from a
total of 728 patients. The specificity in the entire study
population was 94.8 %; however, it was significantly lower
in the 42 children included in the study (47.6 %) [32]. In
contrast to these findings, the specificity of the GM assay
was 97.5 % in a prospective study in 64 children under-
going HSCT [33]. Similarly, the diagnostic sensitivity and
specificity of b-D-glucan (BDG) for the diagnosis of can-
didiasis seem to be adequate in adult patients, whereas the
value in the pediatric population is not clear at all. Notably,
a recent study evaluated BDG levels in children specifi-
cally not at risk for IFI and reported higher baseline levels
of the assay in children compared with adults [34].
Recently, a new indirect test was developed: T2MR and
T2Candida, a miniaturized magnetic based diagnostic
Clin Transl Imaging (2016) 4:57–72 59
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approach that measures how water molecules react in the
presence of a magnetic field. The method is capable of
detecting molecular targets such as DNA. It is reported to
be able to detect Candida on whole blood in cases where
the concentration of Candida in the blood is too low to be
detected by blood culture as would occur in culture nega-
tive disseminated Candidiasis. Trials are still ongoing to




In clinical practice, medical imaging and noninvasive
testing such as GM, BDG, and nucleic acid techniques are
all part of the diagnostic pathway to track fungal infections,
particularly for invasive aspergillosis [36, 37]. Plain
radiographs, ultrasound (US), conventional CT, HR CT,
and MRI all play a role in the diagnosis and management of
fungal infections [11, 37, 38], but all have their limitations.
MRI is particularly useful for identifying infections in the
central nervous system (CNS) and the facial sinuses, which
can be rapidly fatal in acute sinusitis [12]. HR CT has been
found valuable in settling the diagnosis of pulmonary IFIs.
70 % of IFIs are believed to involve the lungs in the
immunocompromised patient. CT is not useful for acute
sinusitis but useful in a chronic setting where it can eval-
uate changes in the bone. US, CT, and MRI are useful in
diagnosing metastatic deposits of IFIs in the intra-abdom-
inal viscera particularly the spleen, kidney, and liver. MRI,
however, was unable to diagnose a spondylodiscitis due to
an IFI in a series where it showed good accuracy for
bacterial spondylodiscitis [39]. We will now discuss more
thoroughly the two most used anatomical imaging modal-
ities in patients with invasive fungal infections.
MRI in the central nervous system
Early hematogenous spread of IFIs initially produces a
cerebritis without abscess formation which cannot be easily
detected by MRI. Later frank abscesses form that can be
picked up by post-gadolinium MRI as reduced diffusion
due to high viscosity and cellularity of fungal pus that may
precede ring enhancement (Fig. 1). The reduced diffusion
in contrast to pyogenic pus is usually heterogeneous. In
disseminated IFIs, a mycotic vasculitis-mediated septic
infarction occurs predominantly at the gray-white junction
or perforating arterioles. This is seen as subtle enhance-
ment and heterogeneous reduced diffusion on MRI. This
anatomical distribution is different from other infarcts,
cerebritis, or abscesses. Cryptococcus or Aspergillus may
seed the cerebrospinal fluid giving variable appearance of
enhanced or non-enhancing lesions of the meninges,
choroid plexus, or ependyma. They may also produce
hydrocephalus with or without white matter edema. In
sinusitis, there is usually enhancement with reduced dif-
fusion noted in the inferior frontal lobe (Fig. 1). There are
specific signs for particular fungal infections beyond the
scope of this review [40].
HR CT for pulmonary aspergillosis
The introduction of HR CT has allowed earlier preemptive
therapy of many patients by identifying lesions highly
suggestive of IFIs in the presence of a positive indirect test.
This is particularly true for invasive pulmonary
aspergillosis. Spores of Aspergillus sp. usually enter the
body through sinuses or respiratory tract infecting them.
Aspergillus infects airways resulting in bronchopneumonia
in the early stages, which may be normal on chest radio-
graph. As the disease progresses nodular appearance or
patchy consolidations may appear. Aspergillus frequently
appears as a single or multiple area of rounded consoli-
dation, which may cavitate. In adults, two key signs exist
on HRCT suggestive for invasive pulmonary aspergillosis:
the halo sign and the air crescent sign. The halo sign is a
ground glass opacity surrounding a pulmonary nodule or
mass and represents hemorrhage (Fig. 2). This sign appears
transiently in the disease and soon the finding changes to
nonspecific findings. The air crescent sign describes the
crescent of air that can be seen in invasive aspergillosis.
Both the halo sign and the air crescent sign are common
and highly suggestive for invasive mold infection in adult
patients [30]. However, various retrospective studies
demonstrated that these CT findings are less specific in
children. In children, other findings including segmental
and multilobar consolidation, peripheral infiltrates, multi-
ple small nodules, and larger peripheral nodular masses are
common, whereas the halo sign is rarely present [41–44].
The use of HRCT in pulmonary candidiasis is less obvious.
Pulmonary candidiasis usually gives small nodular lesions,
which do not cavitate [11, 45, 46]. In general, the findings
of IFIs in children on HR CT are not specific and may
occur in other conditions like bacterial infections or
malignancies [10].
Molecular imaging techniques and hybrid imaging
Nuclear medicine techniques such as positron emission
tomography (PET) detect in vivo pathophysiological
changes before anatomical changes are observed [47, 48].
Modern anatomical imaging modalities such as CT and
MRI depend on structural resolution for visualizing dis-
ease. They are generally of limited value in detecting early
60 Clin Transl Imaging (2016) 4:57–72
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disease irrespective of the cause. Functional and metabolic
images are needed to complement their role in diagnosis of
infection. Modern hybrid imaging modalities (PET/CT and
PET/MRI) provide a unique opportunity to combine the
excellent anatomical resolution with metabolic information
to diagnose, localize, and stage IFIs at a very early stage
[49]. PET/CT has the advantage of being a whole-body
imaging technique; it is not limited to only one region of
the body, so it can provide information of the whole body
in one imaging session and thus is likely to pick up
infectious foci which may not yet have become clinically
apparent.
18F-fluorodeoxyglucose PET
The most commonly used tracer in molecular imaging of
IFIs is 18F-fluorodeoxyglucose (FDG). We performed a
literature search about the role of FDG-PET in IFIs (adults
and children) by entering the words FDG and invasive
fungal infections, FDG and candidiasis, FDG and
aspergillosis, FDG and molds, and FDG and all other
existing fungi. The references of these articles were also
screened and relevant articles were also included. All
included papers have been summarized in 2 tables; the first
one (Table 1) provides an overview of articles that showed
the role of FDG-PET in IFIs in the lung, which accounts for
70 % of IFI cases. Table 2 shows the extrapulmonary
involvement of IFIs, grouped by the site of the body where
the IFI occurred. FDG-PET showed avid uptake across a
wide range of IFIs in different sites of the body. In the
following paragraphs, we provide an overview of what
FDG-PET offers in imaging IFIs in both adults and
children.
Value of FDG-PET/CT in IFIs
The most compelling evidence for the use of FDG-PET/CT
in IFIs is from a prospective study involving a wide range
Fig. 1 MRI scan of the brain in
a patient with acute myeloid
leukemia and CNS aspergillosis.
It shows multiple ring
enhancing lesions in the internal
border zone bilaterally (border
zone between lenticulostriate
perforators and the deep
penetrating cortical branches of
the middle cerebral artery
(MCA) or at the border zone of
deep white matter branches of
the MCA and the anterior
cerebral artery. Red arrow
shows thickening of the mucosa
of the frontal sinus due to acute
sinusitis
Clin Transl Imaging (2016) 4:57–72 61
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of fungi in 30 consecutive adults and children with prob-
able or proven IFI [50]. FDG-PET showed uptake in all
areas noted by conventional imaging making it at least as
sensitive as the total of all other imaging studies per-
formed, including MRI, CT, and US. Furthermore, in this
study, FDG-PET detected more lesions in the liver and
spleen in some cases of hepatosplenic candidiasis. This was
in support with earlier reports which also noted invasive
candidiasis lesions which had not been detected on con-
ventional imaging [51, 52]. These metastatic foci most
likely were identified early in disease where the anatomical
changes associated with infection were not visible yet. In
patients with aspergillosis where HR CT has made an
impact of early diagnosis, FDG-PET/CT not only detected
all active lesions, but also was able to correctly distinguish
inactive noninvasive aspergilloma from active disease.
This is of particular importance in children in whom
HSCT, SOT, or chemotherapy is being considered. This
study further highlights the role of FDG-PET/CT in therapy
response, which was assessed in 20 % (6 out of 30) of their
patients. Due to the small number of patients that were
scanned also for therapy response, they could not conclude
if FDG-PET is also useful for therapy evaluation [50].
Role of FDG-PET in staging IFIs
The overall agreement of all studies is that FDG-PET/CT is
useful in staging IFIs. It has the advantage of being a
whole-body imaging modality and is able to detect meta-
static infectious foci, which are not detected by other
imaging studies. This phenomenon was consistently
demonstrated in a number of papers [49–51]. It will be
helpful before the onset of therapy to know the extent of
the infection and the organs involved, not only to correctly
stage it during infection, but also to decide later if the
infection disappeared and after completion to exclude
recurrence of the fungal infection. An example of a patient
(10-year-old girl) with disseminated fungal infection is
shown in Fig. 3.
Despite the aspecific uptake of FDG, a possible diag-
nosis can be made based on the uptake pattern of FDG and
in light of the clinical findings, and other diagnostic tests.
However, histological confirmation must always be per-
formed for a final diagnosis. FDG-PET is able to define the
site(s) of active infection where biopsy is likely to provide
the correct diagnosis. The finding of high bilateral uptake
in the adrenal glands in an immunocompromised patient
must raise the suspicion of a fungal infection. The presence
of multiple round lesions widely spread throughout the
body or in the liver or spleen in a patient with risk factors
for IFIs should lead to suspect Candida infection. The
predictive value of this diagnosis is further strengthened if
there is also esophageal uptake to suggest esophageal
candidiasis. Aspergillus sp. lesions are usually bigger and
may show a central area of decreased metabolism (cold
center) most likely to the angio-invasive nature of the fungi
causing necrosis due to an infective thrombotic vasculitis
(see also Fig. 4).
Role of FDG-PET in therapy monitoring of patients
with IFIs
Several authors demonstrated the ability of FDG-PET in
monitoring therapy of patients with IFIs [12, 52, 64, 65, 73,
80, 82, 84, 85, 92]. This is particularly crucial in dissem-
inated and deep organ infection without fungemia. Some
treatment protocols recommend that antifungal drugs
should be given for a number of weeks in patients with
suspected IFIs, also when blood cultures are negative. IFIs
in immunocompromised patients are life threatening, and
antifungal therapy is not only extensive, but must also be
prolonged for a long time (depending on which fungal
infection 6 months–2 years). In cases where there is no
fungemia, the duration of therapy becomes ambiguous. In
case of immunocompromised patients being evaluated for
HSCT or SOT, it is important to know if all residual IFI are
cleared before these procedures are undertaken. Clearly, it
is of invaluable importance to have a noninvasive whole-
body technique to localize all fungal lesions and to have a
possibility to monitor disease activity to decide if therapy
can be stopped, or should be prolonged or switched. In
disseminated candidiasis, lesions seen on US, CT, or MRI
have been found to persist for a long time after successful
antifungal treatment due to, e.g., fibrosis and therefore
Fig. 2 HR CT chest scan demonstrating a biopsy-proven Aspergillus
sp. infection. The pleural-based lesion shows surrounding glass
ground appearance on the free edge. The presence of this intrapleural
lesion shows the halo sign, a lesion typically seen early in
Aspergillosis
62 Clin Transl Imaging (2016) 4:57–72
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Table 1 Overview of available papers in literature on pulmonary IFIs




Significant additional findings with FDG-PET
Camus et al. [67] Anticancer Res Candidiasis 3 Useful in evaluation of febrile neutropenia
Aspergillosis 4
Kono et al. [53] Clin Nucl Med Pneumocystis
jirovecii
1 Positive when CT was equivocal
Reyes et al. [58] Lung Coccidiomycosis 12 SUV cannot differentiate between fungal and
malignant lesions; beware of false positive
findings in patients with lung cancer
Sharma et al. [59] AJR Am J Roentgenol Aspergillus 1 Useful in assessing if IFI deposit was active
Cryptococcus 1 Mimics lung cancer
Mucormycosis 1 Rare presentation detected by PET
Wang et al. [59] Int J Infect Dis. Cryptococcus 1 Mimics primary lung cancer with bone metastasis
Kim et al. [74] J Comput Assist
Tomogr
Aspergillosis 24 Distinguished invasive aspergillosis from
noninvasive pulmonary aspergillosis
Hamerschlak et al. [61] Einstein (Sao Paulo) Cryptococcus 1 False positive lymphoma
Baxter et al. [72] Thorax Aspergillosis 1 Mimics lung cancer
Ahn et al. [71] Thyroid Aspergillosis 1 Mimics metastatic thyroid cancer
Vahid et al. [54] MedGenMed Blastomycosis 1 Mimics lung cancer
Nishikawa et al. [70] Kyobu Geka Aspergillosis 1 Mimics a tuberculoma




Dang et al. [55] Clin Nucl Med Mucormycosis 1 Rare presentation of IFI detected by PET guided
biopsy
Xu et al. [73] Clin Nucl Med Candidiasis 1 Monitor antifungal therapy
Nakazato et al. [79] Ann Hematol Pneumocystis
jirovecii
1 Useful for early diagnosis of IFI
Avet et al. [52] EJNMMI Candidiasis 1 Lesion detected on completion of antifungal. Not
previously detected
Sonet et al. [69] Ann Hematol Aspergillosis 1 Mimics lymphoma
Vahid et al. [54] MedGenMed Blastomycosis 1 Mimics primary lung cancer
Igai et al. [62] Eur J Cardiothorac
Surg
Cryptococcus 6 Mimics lung cancer
Salhab et al. [63] J Cardiothorac Surg Histoplasmosis 1 Mimics primary lung cancer
Bleeker-Rovers et al.
[75]
J Nucl Med Candidiasis 9 Useful in detecting metastatic foci of IFI
Bleeker-Rovers et al.
[51]
Clin Microbiol Infect Candidiasis 3 Lung lesions were not seen on CT
Wilkinson et al. [68] Clin Nucl Med Aspergillosis 1 Mimics lung cancer
Theobald et al. [66] Radiologe Aspergillosis 2 Determined extent of spread of disease
Croft et al. [60] Lung Cancer Histoplasmosis 2 False positive in lung cancer evaluation
Coccidiomycosis 1
Franzius et al. [65] Clin Nucl Med Aspergillosis 1 Useful for monitoring therapy
Ozsahin et al. [64] Blood Aspergillosis 1 Monitored infection to allow during immune
suppressive procedure
O’Doherty et al. [56] J Nucl Med Cryptococcus 2 Helped determine cause of symptoms in HIV
patients
Chamilos et al. [94] Med Mycol Aspergillosis 8 Detected all lesions seen on other imaging
modalities, Monitored therapy and revealed extra
pulmonary occult site
Clin Transl Imaging (2016) 4:57–72 63
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these imaging modalities may have limited roles in
assessing therapeutic effect and guiding therapy. FDG-PET
will provide accurate information on therapeutic response
especially for residual focal deposits in disseminated can-
didiasis. In one publication, FDG correctly predicted dis-
ease progression where MRI findings suggested
improvement [12]. In another study, after completion of
antifungal therapy for hepatosplenic and renal abscess
before restarting chemotherapy, FDG-PET/CT detected
lesions in the skeletal, cardiac muscles and the lungs
showing antifungal treatment failure; hence, a different
antifungal was given and lesions resolved [52].
FDG-PET in IFIs in children
In our review of the available literature, we found that data
on the use of FDG-PET in children were very scarce.
15.3 % of the available papers (8/52) included children
(Table 3), but even within these papers children were under
represented with only 24.3 % (9/37) of cases reported
involving patients less than 18 years. In the children
reviewed, most were infected by the two most common
causes of IFIs, Aspergillus and Candida sp. There were
more cases involving Aspergillus than Candida sp. (5 vs.
2), probably underscoring the higher mortality associated
with the former. There were two cases of IFIs caused by
one of the rarer causes of IFI, Zygomycosis (which
includes Mucormycosis). In the limited number of cases
presented, the findings on FDG-PET did not differ signif-
icantly between children and adults. Indeed, in a 6-year-old
patient with IFI, it was the pattern of uptake that was
similar to the uptake in adults. This enabled a diagnosis of
a Candida infection to be made rather than a recurrent
malignant disease when other imaging modalities were
unhelpful in this regard [76]. In all cases of children pre-
sented, the IFI lesions showed uptake similar to the cases in
adults. The response of FDG-PET to antifungal therapy
was also similar. In one case, in an era where there were
limited options of antifungal therapy compared to the
current situation, FDG-PET was able to carefully monitor
the IFI in a patient which had not responded to antifungal
therapy and allowed bone marrow transplantation to be
carried out [44]. The differences in imaging findings
between children and adults with aspergillosis on HR CT
had to do with cavitations which occur later in the disease.
As FDG-PET relies on molecular changes which precede
these anatomical changes, it is unlikely this difference
noted in HR CT would be observed with FDG-PET. FDG-
PET, as is the case in adults, was able to detect lesions in
children with neutropenia [56]; this is consistent with a
review of FDG-PET in febrile neutropenia [93]. In one case
involving Mucormycosis sp. in children, FDG-PET was not
only able to detect lesions but also proved to be superior in
monitoring the disease when compared to MRI [12].
Figure 4 shows the use ofFDG-PET inclinical practice and
how FDG-PET is important even with the development of
several new diagnostic tests that aremore sensitive than blood
culture such as T2MRandT2Candida. These tests provide the
clinician an idea of the presence of the fungi even at very low
levels, but are not able to tell how the fungi in different lesions
in the body respond to the antifungal therapy. As this fig-
ure clearly demonstrates, there was response of some liver
lesions but also new lesions developed after 6 months of
antifungal therapy. Based on this second FDG-PET scan in
this 3-year-old girl, a new antifungal drug regimen was star-
ted. Three months after the start of this new treatment, most
liver lesions responded completely leaving only one large
lesion with a large necrotic center and increased peripheral
metabolic activity. Eventually, this lesion was surgically
removed and pathology indeed revealed an encapsulated
fungal lesion. This different response of the different lesions
illustrates how FDG-PET imaging is able to help in therapy
decision making in children with IFIs.
Limitations of FDG-PET to image IFIs in children
First of all, as mentioned earlier, the nonspecific uptake of
FDG makes it impossible with this tracer to differentiate
Table 1 continued




Significant additional findings with FDG-PET
Chamilos et al. [94] Med Mycol Zygomycosis 5 Detected all lesions seen on other imaging
modalities, was helpful in distinguishing infection
from malignancy
Ritz et al. [95] Eur J Pediatr Zygomycosis 1 Therapy monitoring
Ho et al. [96] Br J Haematol Aspergillosis 1 Therapy monitoring
Go et al. [97] Acta Neurochir Aspergillosis 1 Mimics lung cancer
Eubank et al. [98] J Clin Oncology Aspergillosis 1 Mimics lung cancer
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Table 2 Overview of available papers in literature on extrapulmonary IFIs by site of infection
Site Author date Journal Type of IFI No of
patients
Relevant comment or finding of
FDG-PET
Liver Hot et al. [50] Clin Microbiol Infect Aspergillus 1 3 liver lesions noted
Liver Candida 10 More lesion found by FDG-PET in
the liver (3 cases). CT and US
did not see lesion in one case
Liver Miyazaki et al. [80] Ann Hematol Yeast-like 1 Useful for therapy monitoring
Liver Xu et al. [73] Clin Nucl Med Candida 3 Useful for therapy monitoring
Liver Teyton et al. [85] Clin Nucl Med Candida Useful for therapy monitoring
Liver Avet et al. [52] EJNMMI Candida 1 Detected after completion of
antifungal therapy
Liver Sharma et al. [49] AJR Am J Roentgenol Candida 1 FDG-PET found more lesions than
CT
Spleen Hot et al. [50] Clin Microbiol Infect Candida 7 FDG-PET found more lesions in
the spleen in 3 cases
Spleen Tibu´rcio et al. [76] BMC Pediatr Candida 1 FDG-PET Helps in showing IFI
metastatic foci when other
modalities were equivocal
Spleen Avet et al. [52] EJNMMI Candida 1 Detected active lesion after
completion of antifungal therapy
Spleen Teyton et al. [85] Clin Nucl Med Candida 1 Useful for therapy monitoring
Spleen Ritz et al. [95] Eur J Pediatr Zygomycosis 1 Detection of occult (extra
pulmonary) lesion and therapy
monitoring
Kidneys Avet et al. [52] EJNMI Candida 1 Detected active lesion after
completion of antifungal
chemotherapy
Bones Sharma et al. [49] Sharma P et al. 2014 Cryptococcus 1 FDG-PET shows systemic IFIs
involving boneMucormycosis
Bone Hot et al. [50] Clin Microbiol Infect Mycetoma 2 FDG-PET demonstrates soft tissue
and bone involvementJoints Phomopsis 1
Bone Wang et al. [59] Int J Infect Dis Cryptococcus Mimics metastatic cancer-primary
in lung
Bone Karunanithi et al.
[78]
Clin Nucl Med Histoplasma 1 Useful for rare presentation of
IFIs- isolated sternum
Bone Morooka et al. [83] Jpn J Radiol Candida 1 Directed biopsy to diagnose IFI
Joints Fuster D et al. [46] EJNMMI Aspergillus 1 Diagnosed IFI spondylodiscitis
when MRI did not
Adrenal gland Altinmakas et al. [77] Clin Imaging Candida 1 1. Alerts the possibility of IFIs
when intense bilateral adrenal
uptake is observed
2. Therapy monitoring for Refs.
[88, 89] in addition to above
Histoplasma 1
Sharma et al. [49] AJR Am J Roentgenol Cryptococcus 1
Histoplasma 1
Padma et al. [87] Indian J Med Res Histoplasma 1
Kasaliwal et al. [88] Clin Nucl Med Histoplasma 1
Tsai et al. [89] Clin Imaging Histoplasma 1
Umoeka et al. [90] Eur Radiol Histoplasma 1




Aspergilloma 1 FDG-PET useful for guiding
biopsy
CNS Dubbioso et al. [92] J Neurol Sci Cryptococcus 1 Useful for therapy monitoring
Rare CNS presentation
CNS Chamilos et al. [94] Med Mycol Aspergillus 1 Revealed an occult infection-
whole-body imaging done
CNS Hanson et al. [100] J Comput Assist
Tomogr
Aspergillus 1 Detected CNS involvement
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completely between fungal infections, bacterial infections,
malignancy, or inflammatory lesions. Furthermore, FDG is
taken up in high amounts in the brain and in the heart and
excreted by the kidneys and the bladder, thereby limiting
the detection of fungal infections in these organs. In some
of the reported cases, FDG-PET was used to detect IFIs in
the brain [91]. In our opinion, MRI should be used when
having suspicion of fungal lesions in the brain. Hybrid
imaging with MRI will most likely overcome this limita-
tion [101]. Physiological FDG uptake in the heart can be
avoided by using a low carbohydrate diet for 24 h before
the administration of the FDG, thereby forcing the heart to
switch from a glucose metabolism to a free fatty metabo-
lism. However, this preparation may not always be possible
to execute in very sick children on the ICU. Fungal lesions
in the kidneys can be visible on FDG-PET/CT, by clearly
defining which uptake is based on fungal lesions in the
parenchyma and which uptake is caused by excretion by
the collecting system.
Overall, the FDG-PET/CT procedure (depending if a
low dose CT or also a diagnostic CT is performed) takes
approximately 80–100 min, including the 60 min waiting
time between administration of FDG and start of the scan.
This may be too long for children, especially since they are
not allowed to move or speak. Therefore, in some cases,
sedation may be required. In all cases, both the child and
the parents or guardian should be fully aware of the pro-
cedure and given a familiarization tour. This may reduce
anxiety and obviate the need for sedation. Recently,
educative cartoon books for children were published that
explain the imaging procedure in a funny easy way to
children [102]. This may also be helpful to reduce anxiety
before the procedure.
A last limitation: both PET and CT are procedures
involve the use of ionizing radiation. The tissues of chil-
dren are particularly sensitive to radiation. Both the refer-
ring clinicians and the nuclear medicine physicians have to
be fully aware of this. In situations where several PET/CT
Table 2 continued
Site Author date Journal Type of IFI No of
patients
Relevant comment or finding of
FDG-PET
Kidney Sharma et al. [49] AJR Am J Roentgenol Mucormycosis 1 Defined extent of sinusitis and











Altini et al. [12] Clin Nucl Med Mucormycosis 1 Correctly predicted disease
progression in contrast to MRI





Liu et al. [57] Clin Nucl Med Mucormycosis 1 Serial scans helped modify
antifungal therapy.
Maxillary sinus Kawabe et al. [99] Ann Nucl Med Aspergillus 1 Compared to 67Ga citrate uptake
Aortic valve
(prosthetic)
Wallner et al. [82] Herz Candida 1 Useful for evaluation of therapy
for IFI endocarditis
Aorta Roux et al. [81] Rev Med Interne Candida 1 Contributed to the diagnosis of
mycotic aneurysm
Lymph nodes Sharma et al. [49] AJR Am J Roentgenol Cryptococcus 2 Mimics malignant metastatic node
Lymph nodes Nakazato et al. [79] Ann Hematol Pneumocystis
jirovecii
1 Useful for early diagnosis of IFI
Lymph nodes Mackie et al. [91] Clin Nucl Med Histoplasma 1 Mimics malignant metastatic node
Muscles and
myocardium
Avet et al. [52] EJNMMI Candida 1 Lesions previously undetected
were identified on completion of
antifungal therapy
Esophagus Shrikanthan et al.
[84]
Clin Nucl Med. Candida 1 Uptake concealed esophageal
cancer
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scans are performed for therapy follow-up, we recommend
to perform a diagnostic CT for the initial PET/CT study
and follow-up with only a low dose CT for anatomical
localization and attenuation correction. Though not widely
available at this moment, PET/MRI has the advantage of
the non-radiation part of the MRI and could be of absolute
use in children who require several follow-up scans.
Other available tracers
Fungal infections have been imaged in the past with several
SPECT tracers such as technetium-99 m (99mTc)-labeled
fluconazole, 99mTc-labeled ubiquicidin, and 99mTc-labeled
lactoferrin-derived peptides, such as 99mTc-CBP21 and
T99mTc-hLF 1-11. The peptides were rapidly taken up at
sites of infection and not at inflammatory but sterile sites;
however, they did not discriminate between fungi and
bacteria. 99mTc-fluconazole accumulated only in viable
Candida infection and uptake correlated very well with the
number of fungi present. It did not accumulate in bacteria
of Aspergillus fumigates. All these SPECT-based tracers
also showed promises for therapy monitoring [103]. Flu-
conazole was also labeled with PET radionuclide 18F.
However, the results were relatively disappointing. There
was a poor accumulation at infected sites and high amount
of activity was detected in the liver decreasing its sensi-
tivity to detect Candida infections. The reason of the dif-
ference between this PET tracer and its SPECT equivalent
was the different labeling methods resulting in 18F-flu-
conazole being much more lipophilic than 99mTc-flucona-
zole, resulting in poorer imaging characteristics [103, 104].
Fig. 3 Disseminated candidiasis in a 10-year-old girl with acute
lymphocytic leukemia on chemotherapy. The pattern of widespread
lesions in the muscles and involvement of the esophagus points
towards an infection with candida (later on proven by biopsy)
Fig. 4 Example of use of FDG-PET in therapy monitoring in a
2-year-old girl with Langerhans cell histiocytosis and bone marrow
transplantation. She was diagnosed (after biopsy) with aspergillus
lesions in the liver. a Baseline FDG-PET scan, MIP image, revealing
multiple fungal lesions in the liver. b FDG-PET scan after 6 months
of antifungal therapy, showing decrease in uptake of some liver
lesions, but increase of other liver lesions. Based on these findings,
antifungal treatment was switched. c FDG-PET scan 3 months after
therapy switch, revealing disappearing of all liver lesions expect one
which became larger in time. Eventually this lesion was surgically
removed, showing an encapsulated fungal lesion, which could not be
reached by the antifungal drugs. Note also the decreased uptake in the
brain at the third scan. This scan was performed under sedation
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68Ga-labeled tracers have recently attracted great clini-
cal interest for molecular imaging procedures using PET.
In mice 68Ga-citrate labeled with Triacetylfusarinine C
(TAFC) and ferrioxamine E (FOXE) has been shown to be
highly sensitive for Aspergillus imaging [105]. TAFC and
FOXE are common trihydroxamate-type siderophores with
relatively low molecular weight produced by fungi, bac-
teria, and some plants for scavenging iron making it
available to the organism. These 68Ga-siderophores were
found to be superior to 68Ga–citrate which had a slow
excretion and high blood pool uptake [105, 106]. 67Ga-
citrate was previously used in fungal infections and in one
study it was compared with FDG [99]. It was noted to be
able to accumulate in IFI lesions without blood vessel in an
area where FDG showed minimal uptake; however, in
areas of IFI with relatively preserved vasculature, uptake of
FDG was more intense [99]. Further studies are necessary
to determine whether 68Ga-citrate has advantages over
FDG in humans. In another infection study, 68Ga citrate
was found to detect with high sensitivity bacterial bone
infections; no uptake was seen in sterile inflammation
[107].
Newer radiolabelled targets such as chitin (a component
of fungal cell wall that are absent from mammals) may be
an interesting target for fungal infection imaging in the
future. SPECT tracers targeted against chitin and the
enzyme that degrades it (Iodine-123 labeled chitinase) has
been found useful in imaging IFIs [103, 108, 109]. Further
studies exploring novel radioligands capable of differenti-
ating fungal from bacterial infections and also able to
discriminate sterile inflammatory sites from infections are
definitely warranted [103].
Conclusions
Invasive fungal infections in children have a high mor-
bidity and mortality. Early diagnosis and initiation of
therapy is essential. Several diagnostic tests exist; how-
ever, all have their limitation. Literature on the use of
nuclear imaging techniques in children with invasive
fungal infections is scarce. However, based on studies in
adults and based on clinical expertise, FDG-PET/CT
offers important added value in both staging and therapy
monitoring. FDG-PET is able to non-invasively detect
all fungal lesions within the body (even in the presence
of severe neutropenia [110]), is able to differentiate
between active and inactive fungal infections, and is
able to tell the clinician whether the antifungal therapy
is helping, and should be stopped, switched, or
continued.
Prospective multicenter studies should be started to
achieve robust evidence based data to enable us to develop
relevant diagnostic and therapeutic flow charts when to use
which imaging modality in which stage of the disease.
Table 3 Overview of available literature studies where children with IFIs were documented






16 years Acute myeloid leukemia and
completed chemotherapy
3 months
Mucormycosis sp.-nasal sinuses, valuable tool for initial






6 years Chronic granulomatous disease
and interferon-gamma therapy
Aspergillus sp.-lung, uptake in a suspected case of invasive
pulmonary was persistent on follow-up
Avet et al.
[52]
EJNMMI 16 years Acute leukemia and completion
of chemotherapy
Candida sp.-disseminated. Previously undiagnosed







6 years Neuroblastoma on treatment with
febrile neutropenia









Chronic granulomatous disease Aspergillus sp.-lung, Staged disease, diagnosed in twin sister




Blood 8 years X-linked chronic granulomatous
disease
Aspergillosis sp.- lungs, accurate monitoring of infection













9-year old Burkitts lymphoma on
chemotherapy
Zygomycosis sp.-lung and spleen. Detected occult infection
and used to monitor therapy
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